Copper cell death splits into two routes that converge on mitochondria — in lab models
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Cells walk a copper tightrope: the metal is a cofactor for mitochondrial respiration and antioxidant defense, and a poison when it accumulates. This study maps two distinct ways excess copper kills cancer cells — and shows both roads end inside mitochondria.
What are the two routes?
In canonical cuproptosis, FDX1 reduces copper(II) delivered by elesclomol to copper(I), driving rapid oligomerization of lipoylated mitochondrial proteins and proteotoxic stress. Neocuproine instead triggered a copper-dependent death that proceeded without FDX1 — which the team terms non-canonical cuproptosis — yet still rapidly induced oligomerization of lipoylated DLAT, an early convergence point. Limited-proteolysis profiling identified the copper(I) chaperone ATOX1 as a contributor specific to the non-canonical route: depleting ATOX1 partially blunted neocuproine toxicity but not elesclomol toxicity.
Which cells were vulnerable — and what helped them survive?
Across 436 cancer cell lines, sensitivity to both compounds tracked with oxidative-phosphorylation transcriptional programs; neocuproine-sensitive cells additionally scored higher for mesenchymal / epithelial-mesenchymal-transition signatures. Whole-genome CRISPR activation screening found divergent survival programs: proteasomal and lysosomal cleanup pathways for neocuproine (blocking them amplified killing), versus PI3K, JAK-STAT and MAPK signaling, oxidative phosphorylation and glutathione metabolism for elesclomol. Reactive oxygen species and apoptotic features appeared late and, by the authors' controls, were consequences rather than causes.
What has this not shown?
Everything here is cancer cell lines, genetic screens and preclinical assays. FDX1 dependency, ATOX1 handling, the OXPHOS/EMT cell state and proteostasis pathways are candidate biomarkers and vulnerabilities the authors flag for validation — not clinical predictors, and not a treatment anyone can receive today.
Frequently asked questions
What is cuproptosis?
Cuproptosis is a copper-dependent form of regulated cell death. Excess copper binds lipoylated proteins of the mitochondrial TCA cycle, causing them to aggregate, destabilizing iron-sulfur proteins and producing proteotoxic stress that kills the cell.
What did this study find that is new?
It defined a second, non-canonical cuproptosis route triggered by neocuproine that does not require the mitochondrial enzyme FDX1 and involves the copper chaperone ATOX1, while still converging with the canonical elesclomol route on mitochondrial protein aggregation and respiratory failure.
Could this become a cancer treatment?
That is the long-term hope the authors raise — candidate biomarkers and vulnerabilities for further study — but the evidence is from cancer cell lines and preclinical assays only. No animal efficacy or human treatment result is reported.
Where the evidence stands
- Established: Copper is an essential cofactor for mitochondrial respiration; excess copper can kill cells by cuproptosis, in which copper binds lipoylated TCA-cycle proteins, causing aggregation, iron-sulfur protein loss and proteotoxic stress, with FDX1 as a key mediator for elesclomol.
- Preliminary: In cancer cell lines and screens (Molecular Cancer, Oct 24, 2026), neocuproine induced an FDX1-independent, ATOX1-linked non-canonical cuproptosis that converged with the canonical route on DLAT oligomerization, respiratory dysfunction and mitochondrial collapse.
- Absent: Animal efficacy, human data, and any validated biomarker or therapy exploiting either cuproptosis route.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.